...
机译:CD5(+)MYC +预测弥漫性大B细胞淋巴瘤的预后更糟
Jiangnan Univ Affiliated Hosp Dept Oncol 200 Huihe Rd Wuxi 214000 Jiangsu Peoples R China;
Jiangnan Univ Affiliated Hosp Dept Hematol Wuxi 214000 Jiangsu Peoples R China;
Jiangnan Univ Affiliated Hosp Dept Pathol Wuxi 214000 Jiangsu Peoples R China;
Jiangnan Univ Affiliated Hosp Dept Oncol 200 Huihe Rd Wuxi 214000 Jiangsu Peoples R China;
Jiangnan Univ Affiliated Hosp Dept Oncol 200 Huihe Rd Wuxi 214000 Jiangsu Peoples R China;
Jiangnan Univ Affiliated Hosp Dept Oncol 200 Huihe Rd Wuxi 214000 Jiangsu Peoples R China;
Jiangnan Univ Affiliated Hosp Dept Hematol Wuxi 214000 Jiangsu Peoples R China;
Jiangnan Univ Affiliated Hosp Dept Pathol Wuxi 214000 Jiangsu Peoples R China;
Jiangnan Univ Affiliated Hosp Dept Oncol 200 Huihe Rd Wuxi 214000 Jiangsu Peoples R China;
CD5; Diffuse large B-cell lymphoma; MYC; Prognosis; Survival;
机译:CD5(+)MYC +预测弥漫性大B细胞淋巴瘤的预后更糟
机译:CD5和CD43的共表达预测弥漫性大B细胞淋巴瘤的预后较差
机译:MYC拷贝数畸变预测弥漫性大B细胞淋巴瘤患者的预后更差
机译:通过深度学习预测弥漫性大B细胞淋巴瘤标本的MYC易位
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:CD5和CD43的共表达预示弥漫性大B细胞淋巴瘤的预后较差
机译:次要皮肤弥漫性大B细胞淋巴瘤具有更高的国际预后指数评分和比弥漫性大B细胞淋巴瘤,腿型预后更差